Please login to the form below

Not currently logged in
Email:
Password:

gene therapy

This page shows the latest gene therapy news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Novartis spends big on ezcema,

Daily brief: Novartis spends big on ezcema,

at the UCL Institute of Ophthalmology, which is a world leader in ocular gene therapy. ... Its expertise in viral vector design and optimisation, advanced gene therapy manufacturing, and technology providing temporal control of gene therapies, has the

Latest news

  • Novartis follows Pfizer and freezes US prices this year Novartis follows Pfizer and freezes US prices this year

    ploughing the cash back into the pipeline-enriching acquisitions of gene therapy company AveXis and radiopharma specialist Advanced Accelerator Applications – and going ahead with the spin-off its Alcon eyecare unit. ... for diffuse large B-cell

  • Pfizer enters late-stage haemophilia B gene therapy trial Pfizer enters late-stage haemophilia B gene therapy trial

    Pfizer enters late-stage haemophilia B gene therapy trial. Race is on to free patients of regular injections. ... Pfizer has begun testing investigational gene therapy fidanacogene elaparvovec for the treatment of hemophilia B, triggering a race against

  • AZ makes gene therapy move with 4DMT alliance AZ makes gene therapy move with 4DMT alliance

    AZ makes gene therapy move with 4DMT alliance. The new partnership will focus on creating an AAV for lung disease. ... The deal between AZ’s Medimmune division and the California-based biotech covers the creation and testing of an adeno-associated

  • Christina Coughlin to leave Immunocore for Tmunity Christina Coughlin to leave Immunocore for Tmunity

    In January it raised $135m in series A to support the clinical development of its next-generation T-cell based immunotherapies, including a CRISPR-edited T-cell receptor therapy. ... It also recruited Novartis’former head of cell therapy Oz Azam, to be

  • VC raises new €270m fund for European biotechs VC raises new €270m fund for European biotechs

    It currently has around 25 companies in its portfolio, including Dutch gene therapy specialist UniQure, UK women’s health start-up KaNDy Therapeutics and US biotech Argos Therapeutics which as an

More from news
Approximately 29 fully matching, plus 137 partially matching documents found.

Latest Intelligence

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but ... This, and near-perpetual reform, continues to confound

  • Leo has its eyes on the prize Leo has its eyes on the prize

    Niels Ryber Finsen received the accolade for his pioneering ultraviolet light therapy in 1903 and experts in the field believe it is time the spotlight was once again turned on the ... The Leo surge will include gene therapy and the flexibility to push

  • Health on instalment Health on instalment

    Standing ready. If all goes to plan, gene therapy, a loose umbrella term for modalities that alter genes to treat or prevent disease, stands at the threshold of enormous clinical success. ... But wait, there’s more: well established and respected

  • The rise of real-world evidence The rise of real-world evidence

    Novartis secured such an outcome-based model for its CAR-T therapy Kymriah. ... Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.

  • A unique ecosystem A unique ecosystem

    Regenerative medicine aims to repair injuries or diseased organs using biomaterials, gene therapy, cell therapy and tissue engineering.

More from intelligence
Approximately 3 fully matching, plus 31 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Weekly industry appointments. GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    Prevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition of Francois Nader. ... advance our pipeline of gene therapy

  • Abeona Therapeutics appoints new additions to board of directors Abeona Therapeutics appoints new additions to board of directors

    He said: “Abeona’s ambitious gene and cell therapies have the promise to bring treatments to patients for whom there are currently no treatment options available. ... He said: “I am excited to be joining Abeona’s board at such a time of momentum

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    been able to go for over a year with no additional myeloma therapy and tolerable adverse effects.”. ... well as a pipeline of other cell and gene therapy candidates.

  • Gyroscope Therapeutics appoints CEO Gyroscope Therapeutics appoints CEO

    Dr Bekkali’s previous leadership positions include global head of the ophthalmology business unit at Sanofi, where she led its ophthalmology strategy towards ocular gene therapy and set up a multidisciplinary ... team. Chris Hollowood, chairman of the

More from appointments
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics